Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus
Update on MIGENIX Agreement with Schering-Plough for Hepatitis C Virus Treatment
July 9th, 2007
MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has received notice that Schering-Plough Corporation ("Schering") will not enter into a second period of exclusivity to negotiate terms of a license agreement for MIGENIX's Hepatitis C Virus ("HCV") product, celgosivir. MIGENIX is, therefore now free to advance discussions with other interested parties. Schering has expressed a willingness to consider providing MIGENIX with guidance on study design and drug supplies in support of celgosivir's further clinical development. The exclusivity with Schering arose in connection with the terms of a Material Transfer and License Option Agreement...
Source: Hepatitis Weekly (2007-07-09)
|
